secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-05-12T13:30:19+00:00
Accession:  0001437749-26-016260
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports Annamycin shows no clinically significant cardiotoxicity in 90-patient pooled analysis
--------------------------------------------------------------------------------

- Pooled analysis of 90 R/R AML patients across 5 trials; 78 had source-verified pre/post ejection fraction assessments.
- No patients met criteria for clinically significant left ventricular dysfunction; mean ejection fraction stable.
- Cardiac safety review conducted by Cleveland Clinic cardio-oncology laboratory.
- Data presented at EHA 2026 Congress; Annamycin dosed beyond conventional anthracycline lifetime limits.
- Management believes results support broader positioning in AML and other oncology indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926016260/0001437749-26-016260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926016260/mbrx20260511d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-016260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer